{"schema_version":"1.0","type":"article","title":"Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer","url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.md","lang":"en","date":"2026-06-21","publish_at":"2026-06-21T08:00:00+08:00","updated_at":"2026-06-21","category":"商業分析系列","topic":"商業分析系列","tags":["Merck","Keytruda","PD-1 VEGF","MK-2010","Oncology","Bispecific antibodies"],"summary":"Merck's more serious positioning of MK-2010 suggests that PD-1/VEGF bispecifics are moving from a watch item to a strategic option in the post-Keytruda oncology landscape.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Why MK-2010 matters","url":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/figure-01.png"},{"alt":"HARMONi-6 changed tone","url":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/figure-02.png"},{"alt":"Next oncology package","url":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-21）。Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer。https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-21-merck-pd1-vegf-mk2010-keytruda.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}